OncoC4, Inc. is a biotechnology company focused on developing innovative immunotherapies for hard-to-treat cancers and Alzheimer's disease. The company utilizes advanced scientific pathways involving immune checkpoints like CTLA-4, CD24, and Siglec to enhance the immune system's ability to identify and eliminate cancer cells. Their goal is to create safer and more effective therapies. The product pipeline includes a variety of therapeutic modalities such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapies. These treatments are designed to tackle the complexities of cancer and neurodegenerative diseases by targeting both innate and adaptive immune checkpoints. Founded by leading immunologists, OncoC4 is supported by a team with extensive experience in clinical development and business strategy. The company is headquartered in Rockville, Maryland, and is dedicated to advancing its clinical pipeline through research partnerships and investor collaborations.
我们正在追踪 OncoC4, Inc. 的市场扩张
OncoC4, Inc. 的国际扩张与竞争对手的对比情况
OncoC4, Inc.你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 OncoC4, Inc.你 | 0 | 0 | — | 0 | 0 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
BioNTech和OncoC4的Gotistobart在肺癌患者中显示比化疗降低超过50%的死亡风险，有潜力成为无化疗的单一疗法。
OncoC4在中国宣武医院为首位参与者进行ONC-841阿尔茨海默症1/2期试验给药,已获NMPA批准。ONC-841是全球首个抗SIGLEC 10抗体。
OncoC4宣布gotistobart获中国NMPA突破性疗法认定，用于治疗鳞状非小细胞肺癌，加速其在中国的开发和审查。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 OncoC4, Inc. 的业务、市场和增长信号的快速解答。
